Literature DB >> 526931

Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin.

G L Neil, S L Kuentzel, J P McGovren.   

Abstract

The chemotherapeutic activity of analogs of the anthracycline antibiotic, nogalamycin, was investigated in the P388 and L1210 leukemias and the B16 melanoma in mice. Among the compounds tested, 7-con-O-methylnogarol was found to have superior activity. Depending on the route and schedule of administration, increases in lifespan (ILS) in excess of 100% were observed in all three tumor systems. Additional testing of 7-con-O-methylnogarol demonstrated significant activity in the murine colon 26 and colon 38 tumors and the CD8F1 mammary tumor. 7-Con-O-methylnogarol was not significantly effective against murine Lewis lung carcinoma, although ILSs of 38% and 29% were achieved in two experiments. Activity was observed against ip inoculated P388 leukemia after ip, sc, oral, and iv drug administration. 7-Con-O-methylnogarol was also highly active (ILS greater than or equal to 120%) after ip drug administration to mice with iv inoculated P388 leukemia. Significant ILS values resulted from a variety of schedules of administration against ip inoculated P388 leukemia and B16 melanoma. Experiments in which the time of single-dose administration was varied prior to the time of ip P388 leukemia inoculation showed that residual drug or bioactive drug-related materials remained in mice for 8 hours after 50 mg/kg administered ip and for 48 hours after 200 mg/kg administered sc.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526931

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  16 in total

1.  Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.

Authors:  E A Eisenhauer; K I Pritchard; D J Perrault; S Verma; J L Pater
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

2.  Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).

Authors:  R L Stephens; P Goodman; E D Crawford; C F Spicer; B A Lowe; F R Ahmann; R Chapman; R B Natale
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

3.  Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns.

Authors:  T Tsuruo; H Kawabata; N Nagumo; H Iida; Y Kitatani; S Tsukagoshi; Y Sakurai
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Phase II trial of menogaril in metastatic adenocarcinoma of the prostate. A Southwest Oncology Group study.

Authors:  S A Taylor; B A Blumenstein; R L Stephens; E D Crawford; B Pistone; J B Hill
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

5.  Menogaril: a new anthracycline agent entering clinical trials.

Authors:  J P McGovren; K G Nelson; M Lassus; J C Cradock; J Plowman; J P Christopher
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

6.  Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia.

Authors:  C Mazurek; J P Dutcher; E L Schwartz; S Garl; L Benson; P H Wiernik
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

7.  A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.

Authors:  G R Weiss; T D Brown; J G Kuhn; D D Von Hoff; R H Earhart; W J Adams; J E Brewer; J D Hosley; D A Kasunic
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

8.  Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study.

Authors:  R B Vance; J J Crowley; J S Macdonald; F R Ahmann
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

9.  Synergistic combination of menogarol and melphalan and other two drug combinations.

Authors:  B K Bhuyan; E G Adams; M Johnson; S L Crampton
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

10.  Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors.

Authors:  M L Zanette; U Tirelli; R Sorio; D Zadro; F Figoli; S Monfardini; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.